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ABSTRACT 
 
Purpose of review 
Just as multiple sclerosis (MS) has long been primarily considered a white matter (WM) 
disease, Alzheimer’s disease (AD) has for decades been regarded only as a grey matter (GM) 
disorder. However, convergent evidences have suggested that WM abnormalities are also 
important components of AD, at the same extent as axonal and neuronal loss is critically involved 
in MS pathophysiology since early clinical stages. These observations have motivated a more 
thorough investigation about the possible mechanisms that could link neuroinflammation and 
neurodegeneration, focusing on β-amyloid (Aβ). 
 Neuroimaging studies have found that patients with AD have widespread WM abnormalities 
already at the earliest disease stages and prior to the presence of Aβ plaques. Moreover, a 
correlation between cerebrospinal fluid (CSF)  Aβ levels and WM lesion load was found. On the 
other hand, recent studies suggest a predictive role for CSF Aβ levels in MS, possibly due in the 
first instance to the reduced capacity for remyelination, consequently to a higher risk of WM 
damage progression, and ultimately to neuronal loss. 
We undertook a review of the recent findings concerning the involvement of  CSF Aβ levels in 
the MS disease course and of the latest evidence of AD related WM abnormalities, with the aim to 
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BIOLOGY OF AMYLOID: STRUCTURE, FUNCTION, AND REGULATION  
Amyloid precursor protein (APP) is a single-pass transmembrane protein which is 
expressed at high levels in the brain. Its main biological function is likely to promote 
cell growth. The APP is cleaved by two pathways. In case of nonamyloidogenic 
pathway, APP is first cleaved by α-secretase, generating membrane-tethered α-C 
terminal fragments (CTFs). The cleavage of APP by α-secretase releases sAPPα 
from the cell surface and leaves an 83-amino-acid C-terminal APP fragment (C83). 
Further processing involves the intramembrane cleavage of α-CTFs by γ-secretase, 
which liberates the P3 (3 kDa) peptide. In the amyloidogenic pathway, cleavage via 
the β- and γ-secretases produces several species of Aβ fragments. β-site APP-
cleaving enzyme 1 (BACE1) is the major β-secretase in the brain. Neurotoxic forms 
of Aβ created by cleavage of APP initially by BACE1 produce the 99-amino-acid C-
terminal fragment of APP (C99) and soluble APPβ, and the C99 is then cleaved by 
γ-secretase to produce Aβ. The C99 fragment generated by β-secretase cleavage 
can be internalized and further processed by γ-secretase at multiple sites to 
produce cleavage fragments of 43, 45, 46, 48, 49 and 51 amino acids that are 
further cleaved to the main final Aβ forms, the 40-amino-acid Aβ40 (Aβ1-40) and the 
42-amino-acid Aβ42 (Aβ1-42), in endocytic compartments,[1]. The γ-secretase 
complex consists of four different proteins, presenilin 1, nicastrin, presenilin 
enhancer 2 and anterior pharynxdefective 1. Presenilin 1 (PSEN 1) is activated by 
auto-processing to generate N- and C-terminal cleavage products that both contain 
aspartyl protease sites that together are required for the activity of the mature γ-
secretase. Moreover, both PSEN1 and presenilin 2 (PSEN2) regulate the 
proteolytic function of γ-secretase, and mutations in these proteins can change the 
activity of γ-secretase. Nicastrin, presenilin enhancer 2 and anterior pharynx-
defective 1 are also critical components of γ-secretase and may modulate enzyme 
activity in response to physiological stimuli,[2].  
 
Aβ monomers aggregate into various types of assemblies, including oligomers, 
protofibrils and amyloid fibrils. In their aggregated form, these peptides are able to 
induce neurotoxicity. In particular, amyloid fibrils are larger and insoluble, and they 
can further assemble into amyloid plaques, while amyloid oligomers are soluble and 
may spread throughout the brain. As defined 80 years ago, the amyloid fibrils must 
display the ‘cross-β’ diffraction pattern caused by the cross-β-sheet motif when 
irradiated with X-rays. The motif is composed of tightly interacting intermolecular β-
sheets, and each β-sheet comprises thousands of identical copies of the same β-
strand that stack through hydrogen bonding. Although the pathological properties of 
amyloid load and propagation remain unknown, the association of amyloid fibrils 
with Alzheimer’s disease (AD) type pathology is strong.  
 
The production of Aβ is normally counterbalanced by several processes, 
including proteolytic degradation, cell-mediated clearance, active transport out of 
the brain, and deposition into insoluble aggregates,[2].  Several evidences suggest 
that proteolytic degradation is a particularly important determinant of cerebral Aβ 
levels and, by extension, of Aβ-associated pathology,[3].  In addition to 
degradation, Aβ released into the extracellular space can be transported between 
different compartments, such as from the brain to the blood or from the blood to the 
brain, and can also be cleared by chaperones, such as apolipoprotein E (ApoE), 
which can affect Aβ metabolism after it is released by cells and influence Aβ 
aggregation, clearance, and transport. The carrier- and receptor-mediated transport 
of Aβ across the blood brain barrier (BBB) regulates brain Aβ levels. The 
concentration of soluble Aβ in the central nervous system (CNS), which is central to 
the formation of neurotoxic oligomeric Aβ species and vascular aggregated forms of 
Aβ, is critically influenced by Aβ transport exchange across the BBB. 
 
Alzheimer's disease (AD) is the most common neurodegenerative disorder, and 
its devastating neuropathology is tightly linked to the cortical deposition of fibrillar 
Aβ plaques. The major component of these deposits is Aβ1-42,[4]. However, 
because of the weak correlation between plaque load and AD pathology, more 
recent findings indicate that Aβ dimers, small diffusible Aβ oligomers, are highly 
toxic and more strictly associated with memory dysfunction in the early stage of 
AD,[5].   Although the toxic oligomers are enriched in β-sheet content, they are in a 
distinct conformation from amyloid fibrils. In vitro, Aβ has been described in many 
states including a membrane-bound monomer, a dimer, small oligomers, worm-like 
fibrils, ring-like oligomers, protofibrils, and dozens of polymorphic mature fibrils,[5].   
Although each of these various structural entities appear to be toxic, it remains 
unclear which of them plays the major role in AD pathophysiology and by which 
mechanism of toxicity. Moreover, the relationship between oligomers and fibrils still 
remains to be established. 
 
The amyloid hypothesis proposes that the fundamental cause of AD lies in the 
deposits of extracellular Aβ peptides,[6]. Mutations in the human APP gene cause 
the development of amyloid plaques and Alzheimer's-like brain pathology, 
especially in early-onset familial cases of AD (EOFAD),[7]. Mutations in the human 
APP gene are close to the γ-secretase site and can increase the Aβ1-42/Aβ1-40 ratio. 
It is reported that mutations that alter residues C-terminal to the Aβ1-42 site reduce 
cleavage efficiency and increase the Aβ1-42/Aβ1-40 ratio,[8]. AD-causing mutations 
also occur in the PSEN1 and PSEN2 genes. Mutations in the human PSEN1 and 
PSEN2 genes affect γ-secretase activity and increase the Aβ1-42/Aβ1-40 ratio. Late-
onset AD (LOAD) is characterized by a pattern of interwoven genetic and non-
genetic factors. These genetic risk-factors may affect one or more pathogenic 
mechanisms, such as increased Aβ production and aggregation; decreased Aβ 
clearance and degradation; increased inflammation; and resistance to γ-secretase 
activity. All these mechanisms are believed to lead to neurodegeneration in AD 
brains,[2].    
 
ROLE OF WM ABNORMALITIES IN AD 
In patients with AD, brain magnetic resonance imaging (MRI) detects frequently 
the presence of focal hyperintensities in the deep and subcortical WM,[9]. Their 
presence seems to increase the risk for conversion from mild cognitive impairment 
(MCI) to AD, and to predict the progression of cognitive symptoms. Moreover, 
diffusion-weighted imaging (DWI) studies have demonstrated the presence of WM 
microstructural changes in AD brains since the preclinical stages of disease,[10].   
Nevertheless, the nature of these WM hyperintensities (WMHs) remains largely 
unclear: traditionally, the main hypothesis considers them as chronic ischaemic 
lesions caused by cerebral microangiopathy.  
 
Chronic hypoperfusion due to small vessel disease represents a potential cause 
for the development of WM degeneration in subjects with and without dementia. It 
is well known that several vascular changes reducing the cerebral blood flow, such 
as hypoxia-induced capillary loss, contribute to the formation of WMHs,[11]. The 
crucial issue is exactly their relationship with ageing and preexisting cardiovascular 
disorders, suggesting that vascular damage may be a predominant mechanism for 
their cause. Cerebral amyloid angiopathy (CAA) has been frequently observed in 
the brains of patients with AD at autopsy,[12]. The vascular amyloid deposition of 
CAA on the walls of the cerebral blood vessels can produce luminal stenosis, 
endothelial damage, thrombosis, thickening of blood vessels and vasospasm. This 
is the reason why CAA has been well accepted as the major cause of ischaemic 
WM damage in AD brains. To minimise the risk of confounding variables associated 
with vascular comorbidities, several studies, have selected patients with no 
remarkable history or risk factors for cardiovascular disease. They consistently 
showed that WMHs represent a crucial feature of AD pathology independently from 
patients’ vascular risk factors and disease stage. 
  
At present, it remains unclear to what extent different factors may contribute in 
determining the accumulation of WMHs in AD brains. It is also unclear to what 
extent cerebral hypoperfusion exacerbates the progression of neurodegenerative 
disease processes such as the accumulation of Aβ,[13]. This lack of information 
provides additional incentive on the importance of broadening knowledge about 
AD-related WM pathology, focusing for instance on the overlapping mechanisms 
linking together amyloid deposition and WM primary neuropathology.  
Several studies suggest that Aβ is toxic to oligodendrocytes,[14]. Although 
amyloid plaques are exceedingly rare in AD WM, the levels of soluble Aβ are 
elevated in the WM,[15]. Thus, a direct exposure of WM oligodendrocytes to 
increased amounts of Aβ is likely to occur,[16].  
 
 11C-Pittsburgh compound B (PiB) positron emission tomography (PET) is 
considered to be a useful tool for evaluating AD. PiB retention in the cortex is 
typically used to distinguish AD from other forms of dementia. Given the recent 
findings showing that WM changes are an important feature of AD, regional WM 
PiB retentions in AD patients were also investigated with conflicting results. Further 
study is required to clarify this issue.  
 
Only few data until are available in literature on the relationship between 
measures of macrostructural and microstructural WM damage and cerebrospinal 
fluid (CSF) Aβ levels in AD. Kalheim and colleagues reported a remarkable extent 
of WM microstructrual damage in patients with MCI who showed pathological CSF 
levels of Aβ1-42,[17]. Additionally, a paper by Dean III et al.,[18] has contributed in 
clarifying the relationship between amyloid pathology and myelin alteration in 
preclinical AD. Measuring whole-brain longitudinal and transverse relaxation times 
and the myelin water fraction (MWF), a significantly negative association was 
observed between MWF and CSF Aβ levels,[18]. Concerning inherited forms of AD, 
Lee and colleagues reported a correlation between WMHs and CSF Aβ levels,[19].   
To better understand the relationship between WMHs and amyloid pathology, it 
was investigated how CSF Aβ levels interact with measures of macrostructural and 
microstructural WM damage,[20]. A group of patients with cognitive decline was 
recruited, classifying them as Aβ(+) and Aβ(−) based on their CSF Aβ levels. It was 
demonstrated that, even accounting for the ageing effect, CSF Aβ levels are the 
best predictor for the accumulation of WMHs: the lower the CSF Aβ levels, the 
higher the total WMHs (Figure 1A). Consistently, Aβ(+) patients showed 
significantly higher WM lesion load (LL) when compared with Aβ(−) patients. 
Moreover, it was not observe any significant difference in WM-LL when stratifying 
patients with AD for disease duration or global cognition. Against this background, it 
can be argued argue that WMHs are likely to occur at an early pathophysiological 
stage of AD. In this picture, these findings suggest that CSF Aβ reduction might be 
associated with the occurrence of WM metabolic damage due to Aβ deposition, 
possibly caused by impairment of pathways implicated in myelination and myelin 
repairing processes,[21,22].    
In conclusion, all these studies suggest that WM lesions and their microstructural 
substrate represent a crucial feature of AD, independent of vascular risk factors and 
disease stage. 
 
ROLE OF B-AMYLOID IN MS 
When taking into account the hypothesis of neurodegeneration as a major 
contributor to MS disability, Aβ1-42 has recently become an interesting candidate for 
its putative role in this process. APP has been detected in MS plaques with a higher 
APP immunoreactivity in actively demyelinating than in chronic lesions, thus 
indicating a modification of APP metabolism across disease stages,[23]. Moreover, 
APP was found upregulated in both acute and chronic MS lesions and has been 
regarded as a sensitive marker of axonal damage,[24]. Reduced CSF Aβ levels 
have already been reported in MS patients,[22,25], although the interpretation of 
these findings remains controversial. A recent study in a relatively small group of 
MS patients revealed that lower baseline levels of CSF Aβ are predictive of a more 
severe disease progression over 3-year clinical follow-up,[22]. Following this 
preliminary study, a larger cohort of MS patients with a longer follow-up was 
recruited, classifying them in those Aβlow and those Aβhigh based on their CSF Aβ 
levels. With respect to the clinical outcome, the Aβlow status was associated with a 
higher risk of disease progression,[26] (Figure 1B and 1C).  As a confirmation of 
this, CSF Aβ levels came out as a predictor of clinical disability.  
 
With respect to the underlying processes that might explain why reduced CSF Aβ 
levels associate to a worse clinical outcome, the spectrum of hypotheses appears 
multifaceted. There is the myelin model that combines the occurrence of WM 
metabolic damage with Aβ deposition,[21]. On the one hand, the inflammation 
increases BACE1 activity, which was previously found increased in patients with 
reduced CSF Aβ levels,[27]. BACE1 is also involved in the cleavage of neuregulin 1 
(NRG1),[28], a protein that plays a crucial role in myelin repair. On the other hand, 
CSF Aβ reduction could depend on APP deposition around injured axons, although 
there is no evidence of Aβ deposition in MS plaques. Nevertheless, these studies 
suggest that CSF Aβ levels may represent a significant feature in MS, as they 
resulted being predictive biomarkers of disease progression,[22,26]. As part of a 
fascinating hypothesis, it can be speculated that lower CSF Aβ levels may be 
associated with a decreased ability to remyelinate CNS axons, with an early WM 
and GM damage, and with a higher probability of clinical disease progression. 
Considering the relationship existing between some genetic factors (i.e., 
apolipoprotein polymorphisms), myelin repair efficiency, and the risk of amyloidosis, 
it is possible that genetic modulations, whose effect is typically observed in old age, 
may have an impact in younger ages only when individuals are affected by a highly 
impacting condition such as MS. A relationship between APOE genotyping and MS 
severity, however, remains poorly investigated and controversial,[29,30]. Similarly, 
the exact role played by Aβ in MS pathophysiology remains to be fully understood. 
 
PET with amyloid tracers (e.g. PiB, florbetapir, florbetaben, flutemetamol) was 
originally developed for imaging of amyloid deposition in neurodegenerative 
disorders and dementia,[31]. Only recently it has been proposed as an imaging 
marker for quantification of myelin loss and repair in MS,[32-35]. Amyloid tracers 
bind extensively to WM, and its uptake decreases in the presence of 
demyelination,[32] (Figure 2). The usefulness of amyloid tracers in MS is 
traditionally considered secondary to their nonspecific binding to WM, possibly 
being trapped in β-sheet structures of myelin proteins or being highly soluble in the 
myelin-associated lipid bilayer,[36]. Acute WM lesions show reduced amyloid tracer 
uptake compared with the normal-appearing WM (NAWM), thus reflecting a more 
extensive myelin loss within the lesions than in the NAWM,[34]. In light of these 
data, amyloid PET tracer WM uptake may be considered as a biomarker of 
demyelination.  
 
Given these premises, amyloid tracer uptake in damaged WM (DWM) and 
NAWM of MS patients divided according to their disease activity was recently 
studied,[37]. It was also investigated possible correlations between amyloid tracer 
uptake and CSF Aβ levels. In line with previous studies,[34,36], first it was found 
that the amyloid tracer uptake in larger WM lesions is reduced compared to that in 
the NAWM, thus confirming the role of amyloid PET as a biomarker of myelin loss. 
Moreover, it was showed that 18F-florbetapir uptake in patients with active disease 
is lower than that in non-active patients, suggesting an interesting link between 
early WM damage and disease activity,[37]. The most interesting finding of this 
study is that the tracer uptake in the NAWM correlates with CSF Aβ levels: the 
lower the uptake, the lower the CSF Aβ concentration,[37] (Figure 1D). It can be 
hypothesized that active patients, i.e. those with lower uptake in both DWM and 
NAWM and with lower CSF Aβ levels, may have a reduced capacity for 
remyelination and consequently a higher risk of disease progression. Strengthening 
this hypothesis, it was also found lower uptake in the NAWM and lower CSF Aβ 
levels in those patients with smaller NAWM volume. In line with these findings and 
the aforementioned hypotheses, the correlation described between amyloid tracer 
uptake and CSF Aβ concentration seems to confirm that amyloid plays a role in the 
progression of WM damage in MS. As part of this speculation, lower CSF Aβ levels 
could be associated with a decreased ability for remyelination of CNS axons, with 
early WM and GM damage, resulting in a higher probability of disease progression. 
 
Β-AMYLOID AND WM DAMAGE 
A big issue that still needs addressing is why CSF Aβ levels correlate with macro 
and/or microstructural WM damage in both conditions, AD and MS. At first sight, it 
seems complicated to identify a single mechanism for these two different 
conditions. As regards MS, the most convincing explanation is that a precocious 
micro-inflammatory milieu increases Aβ secretion. However, both these processes 
(the persistence of inflammation and the Aβ production) exercise mutual influence: 
just as brain’s inflammatory response can increase Aβ secretion (i.e. reactive 
astrocytes increase the expression of BACE1 and, therefore, Aβ production), Aβ 
itself can be considered as a proinflammatory mediator due to its ability to induce 
inflammation,[38]. Furthermore, Aβ can stimulate proinflammatory cytokine release 
from astrocytes. The same applies to AD, even if reversed. Increased amounts of 
Aβ trigger a cascade of neuropathological events, including demyelination, death of 
oligodendroglial cells and mild glial reaction,[39]. And not only that, as well as cell 
dysfunction and alterations in the neurotransmission,[40]. As mentioned above, Aβ 
peptides exert a cytotoxic effect on the oligodendrocyte. As the oligodendrocyte is 
indispensable for the maintenance of the myelin sheath, Aβ-induced 
oligodendrocyte death can subsequently disrupt its integrity. Aβ peptides induce, in 
turn, a micro-inflammatory milieu, which maintains and often further affects the WM 
damage (Figure 3). In any case, it remains to be clarified whether Aβ plays a causal 
role in the injury of the WM or represents only an epiphenomenon of the failure of 
its reparative processes. 
 
As speculation, one single model that could unify these two points of view may 
be the metabolic one, which associates the Aβ deposition with the occurrence of 
WM metabolic damage due to several, partially still unknown factors. In line with 
this hypothesis, the myelin vulnerability could be the key element. The expansion of 
brain volume and connectivity seem largely myelin-driven, over the life-span as in 
the evolutionary trajectory. Human cognitive functions and behaviors are highly 
dependent on later-myelinating oligodendrocytes, cells that continue myelinating 
the circuitry of neural networks,[41]. These later-myelinating oligodendrocytes and 
their myelin are structurally more complex and metabolically overextended. Thus, 
they seem to be especially vulnerable to neuroinflammatory and neurodegenerative 
processes,[42]. As proposed by Haroutunian and colleagues,[41], the human 
species’ exceptional myelination is supported by very recent evolutionary changes 
involving lactate dehydrogenase to augment energy production, peroxisome 
organelle function to augment lipid production, and ApoE to augment lipid 
transport/recycling. The authors explained that these adaptations may have 
evolved in part to support the extremely metabolically expensive processes of 
creating and maintaining a highly myelinated CNS,[41]. In this vision, multiple 
insults to myelin (i.e. inflammatory attacks during MS relapses or metabolic 
overload during neurodegenerative processes) could be directly responsible for Aβ 
secretion and deposition, or indirectly linked to amyloid pathology on this as an 
epiphenomenon of the failure of myelin repairing processes. On the other hand, the 
regional vulnerability to Aβ deposition could explain why the very early GM atrophy 
patterns observed in both AD and MS seem to be consistent and involve the same 
neocortical areas,[43]. In other words, cortical atrophy could be increased in those 
areas known to have the highest early Aβ load, such as the precuneus and the 
anterior and posterior cingulate areas also in MS, suggesting a direct relationship 
between GM atrophy and Aβ deposition in these regions. Morevover, a recent study 
identified a specific set of early Aβ accumulating regions, which largely correspond 
to the default-mode network (DMN), revealing that the hypoconnectivity within the 
DMN and between DMN and the frontoparietal network is associated with low CSF 
Aβ levels,[44]. Interesting results were also obtained with transcranial magnetic 
stimulation protocols, showing in early AD not only the involvement of the 
hippocampus but also of the associative cerebral cortices, suggesting that Aβ-
related pathology would derive from the disturbance of the brain's effective 
connectivity implying abnormal interactions between neuronal systems,[45]. Taken 
together, all these findings seem to confirm that myelin or neuronal selective vulnerability 
may be related to metabolic and/or plastic requirements and not be associated with 
disease-specific pathological processes. 
 
CONCLUSIONS  AND FUTURE DIRECTIONS 
Although further research on amyloid pathology in WM damage is necessary, 
recent studies have demonstrated that (1) Aβ plays a role in MS; (2) WMHs 
represent an early feature of AD; (3) neuroinflammation and neurodegeneration 
often have overlapping and uncertain boundaries; (4) CSF Aβ levels are predictors 
for WM micro- and macrostructural damage in both AD and MS. There are 
additional biomarkers that can be obtained in vivo and could, in combination with 
wet biomarkers, help clarify the relationship between inflammation and 
neurodegeneration. Future studies, possibly with a longitudinal design, should 
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A – Linear regression of total white matter (WM) lesion load in function of CSF β-amyloid 
(Aβ) levels in both AD and non-AD patients. Scattered line shows CSF Aβ threshold for 
AD diagnosis, which was set at the value of 600 pg/ml (adapted from Pietroboni et al.; 
CSF β-amyloid and white matter damage: a new perspective on Alzheimer's disease;  J 
Neurol Neurosurg Psychiatry. 2018 Apr;89(4):352-357.) 
B – Comparison of CSF Aβ levels in MS patients stratified according to EDSS score (<3 or 
≥3) at 5-year follow-up. Threshold was set at the value of 813 pg/ml. 
C – Multiple regression analysis of EDSS score at 5-year follow-up in function of CSF Aβ 
levels (Figures B and C adapted from Pietroboni et al.; CSF β-amyloid predicts prognosis 
in patients with multiple sclerosis;  Mult Scler. 2019 Aug;25(9):1223-1231.) 
D – Comparison of CSF Aβ levels in MS active patients according to their normal-
appearing white matter (NAWM) amyloid tracer mean standard uptake value (SUV) 
(adapted from Pietroboni et al.; Amyloid PET as a marker of normal-appearing white 
matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain 
volumes; Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):280-287.) 
 
FIGURE 2 
Brain MRI and amyloid PET imaging in MS (A) and AD (B). 
A – Left: T1-weighted MRI/PET fusion images. Right: Normal appearing white matter 
(blue) and damaged white matter (red) segmentation on T2-weighted FLAIR MRI. 
B – Grey matter (red), normal appearing white matter (blue) and damaged white matter 




Flowchart showing the putative biological mechanism coupling neuroinflammation and neurodegeneration 
through amyloid-related pathways. 
 
Neuroinflammation is considered the mainstay of multiple sclerosis pathogenesis, although it is reported to 
occur in neurodegenerative diseases as well such as Alzheimer disease. In this scenario, the activation of 
immune response cascade promotes the expression of β-site amyloid precursor protein(APP)-cleaving 
enzyme 1 (BACE1), which is an inflammatory-induced protein. By means of preferential activation of the 
amyloidogenic way, an increased production of Aβ1-42 peptides occurs, which is assumed to exert a direct 
toxic effect on oligodendrocytes. In addition of that, inflammation promotes the overexpression of APP itself 
and reduces the clearance of Aβ1-42  peptides, overall concurring to sustain amyloid pathology accrual. 
Noteworthy, BACE1 is also involved in Neuregulin1 cleavage, presumed to be fundamental for regulation of 
myelination and synaptic plasticity. As a whole, these mechanisms are likely to affect myelin dynamics, 
without regard to the original biological insult that arouse the inflammatory response. Ultimately, the 
inefficiency of damage repair system promotes the persistency of such an inflammatory milieu, further 
enhancing the secretion of the abovementioned toxic amyloid peptides. All these interconnected conditions 
concur to the establishment of a disruptive self-maintaining mechanism of white matter damage progression, 
that ultimately leads to neurodegeneration and clinical disability accrual. 
 
